|
|
|
|
|
PROSPECTUS SUPPLEMENT NO. 3 |
|
|
|
Filed Pursuant to Rule 424(b)(7) |
(to Prospectus dated October 5, 2023) |
|
|
|
Registration No. 333-267683 |
Amprius Technologies, Inc.
This prospectus supplement is being filed to update and supplement the information contained in our prospectus dated October 5, 2023, as
supplemented by the prospectus supplements dated May 13, 2024 and October 23, 2024 (as so supplemented, the Prospectus). Capitalized but undefined terms have the meanings ascribed to such terms in the Prospectus.
This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or
utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the
Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.
Our common stock and public
warrants are listed on the New York Stock Exchange (the NYSE) under the symbols AMPX and AMPX.W, respectively. On December 6, 2024, the last reported sales prices for our common stock and public warrants on
the NYSE were $2.05 and $0.2713, respectively.
We are an emerging growth company, as defined under the federal securities
laws, and, as such, may elect to comply with certain reduced public company reporting requirements.
Investing in
our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in Risk Factors beginning on page 4 of the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities
or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of
this prospectus supplement is December 9, 2024